Mazindol falls within the of the Schedule IV on the DEA drug list. It is a sympathomimetic used to treat obesity in combination with lifestyle modifications. Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than amphetamine, but with some similar side effects.
It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Mazindol is a Schedule IV which means it is . Other drugs like Modafinil  Xanax, serdexmethylphenidate, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Mazindol, and Tramadol in the same class at random are also classified as Schedule IV by the DEA.  in the same class at random are also classified as Schedule IV by the DEA.
Mazindol is a Small Molecule that is categorized for Approved, Investigational but can be dangerous when used recreationally or misused.
The half-life of Mazindol means the amount of time that stays in your system before it is fully absorbed. The halflife of Mazindol is 10–13 hours.
Used in short-term (a few weeks) treatments of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, high blood pressure, diabetes, or hyperlipidemia.
Mazindol is a sympathomimetic amine that stimulates the central nervous system (nerves and brain), leading to increased your heart rate and blood pressure, and decreased appetite. Since the appetite-suppressing effect of the drug tends to decrease after few weeks of treatment, sympathomimetic appetite suppressants are typically used short-term weight-loss program.
Drug name is Mazindol is a sympathomimetic used to treat obesity in combination with lifestyle modifications. which is different from because Mazindol is a sympathomimetic used to treat obesity in combination with lifestyle modifications.
Data obtained suggests that dependence is limited in humans with this compound. It does not produce a high like cocaine. Stimulant abusers do not typically enjoy it so it does not have a high street value.
Mozindol overdose symptoms are similar to that of other CNS stimulants and include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, increased blood pressure and seizures.
Get confidential help 24/7. Call now for:
Related Articles
Get Help Now
Baird IM, Howard AN. A double-blind trial of mazindol using a very low calorie formula diet. International Journal of Obesity. 1977 ;1(3):271-278. PMID: 363631.
Susami Iijima, Yoshiro Sugita, Yoshio Teshima, Yasuo Hishikawa, Therapeutic Effects of Mazindol on Narcolepsy, Sleep, Volume 9, Issue 1, March 1986, Pages 265–268,
National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 4020, Mazindol. Retrieved December 10, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Mazindol.
Stine, S. M., Krystal, J. H., Kosten, T. R., & Charney, D. S. (1995). Mazindol treatment for cocaine dependence. Drug and Alcohol Dependence, 39(3), 245–252.
Medical Advice Disclaimer
Magnified Health Systems aims to improve the quality of life for people struggling with substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited and reviewed by licensed medical professionals. The information we provide is not intended to be a substitute for professional medical advice, diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare providers.
Dr. Bickley graduated from U.C. Irvine with honors: Phi Beta Kappa, Golden Key International Honor Society, Cum Laude. He has been featured on national radio and print media. He is also a frequent lecturer at National Conferences. He holds an A.S. degree in Drug & Alcohol Studies, and two B.A. degrees in Criminology & Psychology, and masters and doctoral degree in Clinical Psychology. He is a licensed California Drug & Alcohol Counselor Level II, a licensed Clinical Supervisor and is certified in treating Eating Disorders.
Call Us Now, Our Admissions Team Is Standing By And Available 24/7.
Head Office Location:
1530 N Federal Hwy Lake Worth, FL 33460
Contact & Feedback:
We are here for you.
We are here for you, Call us and get started!
